EUVIMEDScopri EUVIMED
Crossref

Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas After Liver Transplantation

Bradley T Busebee iD, Jerry Yung-Lun Chin, Kristin Mara, Brad Johnson, Naoki Takahashi, Shounak Majumder, Kymberly D Watt

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15431 ↗

At a glance

Journal article in Clinical Transplantation, 2024. Written by Bradley T Busebee and 6 co-authors. Institution: Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Liver Transplantation, Disease Progression, Pancreatic Neoplasms. 12 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Intraductal papillary mucinous neoplasms (IPMNs) are the most commonly identified pancreatic cystic neoplasms. Incidentally detected IPMNs are common among liver transplant recipients. The risk of IPMN progression to pancreatic cancer in transplant recipients and the impact of immunosuppression on the risk of malignant transformation of IPMN are unclear.

Methods

In this retrospective study of consecutive liver transplant recipients across Mayo Clinic over a 13‐year period, patients were assessed for possible IPMN by automated chart review. Pancreatic cystic lesions were characterized as suspected IPMNs based on imaging criteria. Cox proportional hazards models were used to determine the association between IPMN progression (the development of cancer or worrisome features) and clinical and immunosuppression regimen characteristics.

Results

Of 146 patients with suspected IPMNs, progression occurred in 7 patients (2 cases of IPMN‐associated cancer and 5 cases of worrisome features) over an average follow‐up of 66.6 months. Immunosuppression type, medication number, and tacrolimus trough levels were not associated with IPMN progression ( p > 0.05). Combined kidney and liver transplantation ( p = 0.005) and pretransplant cholangiocarcinoma ( p = 0.012) were associated with IPMN progression.

Conclusion

IPMN progression is rare after liver transplantation even over an extended follow‐up period. The findings were notable for the absence of an association between IPMN progression and immunosuppression regimen. Larger studies are needed given the low incidence.

Subjects

MeSH terms (MEDLINE)

Liver TransplantationDisease ProgressionPancreatic NeoplasmsHumansMaleFemaleRetrospective StudiesMiddle AgedFollow-Up StudiesPrognosisAdenocarcinoma, MucinousRisk FactorsAgedPancreatic Intraductal NeoplasmsCarcinoma, Pancreatic DuctalAdultPostoperative Complications

Author keywords

cancerimmunosuppressantmalignancyneoplasia: risk factors

Authors and institutions

  • Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Health Sciences and Research, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID profiles: Bradley T Busebee

Cite

APA

Busebee, B. T., Chin, J. Y., Mara, K., Johnson, B., Takahashi, N., Majumder, S., & Watt, K. D. (2024). Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas After Liver Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.15431

Vancouver

Busebee BT, Chin JY, Mara K, Johnson B, Takahashi N, Majumder S, et al. Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas After Liver Transplantation. Clinical Transplantation. 2024. doi:10.1111/ctr.15431

BibTeX
@article{Busebee2024,
  author = {Busebee, Bradley T and Chin, Jerry Yung-Lun and Mara, Kristin and Johnson, Brad and Takahashi, Naoki and Majumder, Shounak and Watt, Kymberly D},
  title = {Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas After Liver Transplantation},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15431}
}
Start for free →